

Sarah Zohar

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6428993/sarah-zohar-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers

2,502
citations

27
h-index

47
g-index

109
ext. papers

2,979
ext. citations

3.7
avg, IF

4.78
L-index

#	Paper	IF	Citations
102	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1298-1306	27.4	229
101	Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. <i>Lancet Neurology, The</i> , 2015 , 14, 469-77	24.1	170
100	Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2006 , 8, 60-6	1	159
99	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. <i>Neuro-Oncology</i> , 2010 , 12, 401-8	1	147
98	Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 98-104	2.4	116
97	Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005 , 30, 121-32	2.2	96
96	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. <i>British Journal of Haematology</i> , 2002 , 119, 726-39	4.5	91
95	The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. <i>Statistics in Medicine</i> , 2001 , 20, 2827-43	2.3	85
94	Late morbidity after colon interposition for corrosive esophageal injury: risk factors, management, and outcome. A 20-years experience. <i>Annals of Surgery</i> , 2010 , 252, 271-80	7.8	62
93	Experimental designs for phase I and phase I/II dose-finding studies. <i>British Journal of Cancer</i> , 2006 , 94, 609-13	8.7	53
92	Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. <i>European Journal of Cancer</i> , 2017 , 70, 133-142	7.5	52
91	A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. <i>British Journal of Cancer</i> , 2006 , 95, 253-9	8.7	52
90	Surgery for caustic injuries of the upper gastrointestinal tract. <i>Annals of Surgery</i> , 2012 , 256, 994-1001	7.8	50
89	A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. <i>Pharmaceutical Statistics</i> , 2014 , 13, 247-57	1	41
88	Designs of drug-combination phase I trials in oncology: a systematic review of the literature. <i>Annals of Oncology</i> , 2015 , 26, 669-674	10.3	39
87	Recent developments in adaptive designs for Phase I/II dose-finding studies. <i>Journal of Biopharmaceutical Statistics</i> , 2007 , 17, 1071-83	1.3	35
86	Dose-finding approach for dose escalation with overdose control considering incomplete observations. <i>Statistics in Medicine</i> , 2011 , 30, 1584-94	2.3	34

85	Esophageal replacement by allogenic aorta in a porcine model. <i>Surgery</i> , 2010 , 148, 39-47	3.6	33
84	Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. <i>Contemporary Clinical Trials</i> , 2008 , 29, 608-16	2.3	33
83	Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. <i>Statistics in Medicine</i> , 2013 , 32, 2728-46	2.3	31
82	Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. <i>Computer Methods and Programs in Biomedicine</i> , 2003 , 72, 117-25	6.9	30
81	Competing designs for drug combination in phase I dose-finding clinical trials. <i>Statistics in Medicine</i> , 2015 , 34, 1-12	2.3	29
80	Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. <i>Diseases of the Colon and Rectum</i> , 2011 , 54, 729-35	3.1	29
79	Colopharyngoplasty for the treatment of severe pharyngoesophageal caustic injuries: an audit of 58 patients. <i>Annals of Surgery</i> , 2007 , 246, 721-7	7.8	29
78	Recommendations for the design of therapeutic trials for neonatal seizures. <i>Pediatric Research</i> , 2019 , 85, 943-954	3.2	28
77	Incorporating lower grade toxicity information into dose finding designs. <i>Clinical Trials</i> , 2011 , 8, 370-9	2.2	28
76	Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. <i>Journal of Rheumatology</i> , 2009 , 36, 1460-3	4.1	27
75	Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. <i>Transfusion</i> , 2007 , 47, 1851-7	2.9	27
74	Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. <i>Biometrical Journal</i> , 2017 , 59, 804-825	1.5	25
73	Optimal designs for estimating the most successful dose. <i>Statistics in Medicine</i> , 2006 , 25, 4311-20	2.3	25
72	A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2015 , 64, 215-229	1.5	24
71	Retrospective robustness of the continual reassessment method. <i>Journal of Biopharmaceutical Statistics</i> , 2010 , 20, 1013-25	1.3	24
70	Determination of the optimal sample size for a clinical trial accounting for the population size. <i>Biometrical Journal</i> , 2017 , 59, 609-625	1.5	23
69	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020 , 12, 483-497	1.2	22
68	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. <i>Orphanet Journal of Rare Diseases</i> , 2018 , 13, 186	4.2	22

67	Minimum effective dose of midazolam for sedation of mechanically ventilated neonates. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005 , 30, 479-85	2.2	21
66	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. <i>Orphanet Journal of Rare Diseases</i> , 2017 , 12, 44	4.2	19
65	Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. <i>Journal of the American Statistical Association</i> , 2014 , 109, 931-943	2.8	19
64	Identifying the most successful dose (MSD) in dose-finding studies in cancer. <i>Pharmaceutical Statistics</i> , 2006 , 5, 187-99	1	19
63	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. <i>Statistics in Biopharmaceutical Research</i> , 2020 , 12, 461-477	1.2	19
62	The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. <i>Clinical Cancer Research</i> , 2012 , 18, 5179-87	12.9	18
61	The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. <i>Bone Marrow Transplantation</i> , 2006 , 37, 725-9	4.4	18
60	Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. <i>Statistical Methods in Medical Research</i> , 2018 , 27, 466-479	2.3	17
59	Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. <i>Clinical Trials</i> , 2013 , 10, 414-21	2.2	17
58	Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. <i>Clinical Trials</i> , 2008 , 5, 478-85	2.2	15
57	Decision-theoretic designs for small trials and pilot studies: A review. <i>Statistical Methods in Medical Research</i> , 2016 , 25, 1022-38	2.3	15
56	Bumetanide for neonatal seizures-back from the cotside. <i>Nature Reviews Neurology</i> , 2015 , 11, 724	15	14
55	Application of the continual reassessment method to dose-finding studies in regional anesthesia: an estimate of the ED95 dose for 0.5% bupivacaine for ultrasound-guided supraclavicular block. <i>Anesthesiology</i> , 2013 , 119, 29-35	4.3	14
54	Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. <i>Clinical Trials</i> , 2008 , 5, 595-606	2.2	14
53	Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. <i>Statistical Methods in Medical Research</i> , 2018 , 27, 1860-1877	2.3	13
52	Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. <i>Statistics in Medicine</i> , 2011 , 30, 1563-73	2.3	13
51	Primary hyperparathyroidism from parathyroid microadenoma: specific features and implications for a surgical strategy in the era of minimally invasive parathyroidectomy. <i>Journal of the American College of Surgeons</i> , 2010 , 210, 456-62	4.4	13
50	Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial. <i>BMJ Open</i> , 2019 , 9, e022739	3	11

49	Approaches to sample size calculation for clinical trials in rare diseases. <i>Pharmaceutical Statistics</i> , 2018 , 17, 214-230	1	11
48	Sensitivity of dose-finding studies to observation errors. <i>Contemporary Clinical Trials</i> , 2009 , 30, 523-30	2.3	11
47	An adaptive power prior for sequential clinical trials - Application to bridging studies. <i>Statistical Methods in Medical Research</i> , 2020 , 29, 2282-2294	2.3	11
46	Similar outcomes after primary and secondary esophagocoloplasty for caustic injuries. <i>Annals of Thoracic Surgery</i> , 2012 , 93, 905-12	2.7	10
45	Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas. <i>Pharmaceutical Statistics</i> , 2011 , 10, 218-26	1	10
44	Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design. <i>Journal of Biopharmaceutical Statistics</i> , 2003 , 13, 87-101	1.3	10
43	A Bayesian predictive sample size selection design for single-arm exploratory clinical trials. <i>Statistics in Medicine</i> , 2012 , 31, 4243-54	2.3	9
42	Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial. <i>Clinical Trials</i> , 2013 , 10, 505-14	2.2	9
41	An approach to meta-analysis of dose-finding studies. <i>Statistics in Medicine</i> , 2011 , 30, 2109-16	2.3	9
40	Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?. <i>Bone Marrow Transplantation</i> , 2009 , 43, 919-25	4.4	9
39	A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. <i>Haematologica</i> , 2006 , 91, 550-3	6.6	9
38	Dose-finding designs for cumulative toxicities using multiple constraints. <i>Biostatistics</i> , 2019 , 20, 17-29	3.7	8
37	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. <i>Orphanet Journal of Rare Diseases</i> , 2016 , 11, 16	4.2	8
36	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. <i>BMC Medical Research Methodology</i> , 2018 , 18, 20	4.7	8
35	A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 387-95	6.2	7
34	Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. <i>Statistical Methods in Medical Research</i> , 2019 , 28, 404-418	2.3	7
33	dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. <i>Computer Methods and Programs in Biomedicine</i> , 2018 , 157, 163-177	6.9	6
32	An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety. <i>Statistics in Medicine</i> , 2015 , 34, 3029-39	2.3	6

31	Re: Dose escalation methods in phase I cancer clinical trials. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1732-3; author reply 1733-5	9.7	6
30	Bayesian variable selection based on clinical relevance weights in small sample studies-Application to colon cancer. <i>Statistics in Medicine</i> , 2019 , 38, 2228-2247	2.3	5
29	Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1481-91	5.9	5
28	Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. <i>Statistics in Biopharmaceutical Research</i> , 2020 , 12, 478-482	1.2	5
27	Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. <i>PLoS ONE</i> , 2016 , 11, e0166207	3.7	5
26	What is the ED95 of prilocaine for femoral nerve block using ultrasound?. <i>British Journal of Anaesthesia</i> , 2013 , 110, 831-6	5.4	4
25	Alternate designs for conduct and analysis of phase I cancer trials. <i>Blood</i> , 2001 , 98, 1275-6	2.2	4
24	A Bayesian non-inferiority approach using expertsPmargin elicitation - application to the monitoring of safety events. <i>BMC Medical Research Methodology</i> , 2019 , 19, 187	4.7	2
23	Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. <i>PLoS ONE</i> , 2016 , 11, e0156096	3.7	2
22	Maximum-relevance weighted likelihood estimator: application to the continual reassessment method. <i>Statistics and Its Interface</i> , 2010 , 3, 177-183	0.4	2
21	A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes. <i>Methods of Information in Medicine</i> , 2016 , 55, 4-13	1.5	2
20	Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. <i>Statistical Methods in Medical Research</i> , 2020 , 29, 541-567	2.3	2
19	Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics. <i>Biometrics</i> , 2021 ,	1.8	2
18	A dose finding design for seizure reduction in neonates. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2019 , 68, 427-444	1.5	1
17	Response to comments on Rcompeting designs for drug combination in phase I dose-finding clinical trialsPby G. Yin, R. Lin and N. Wages. <i>Statistics in Medicine</i> , 2015 , 34, 23-6	2.3	1
16	Interest in an original methodology to define the optimal dosage of interferon-alpha-2a in metastatic melanoma patients. <i>Melanoma Research</i> , 2009 , 19, 379-84	3.3	1
15	Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens. <i>Statistics in Medicine</i> , 2021 , 40, 5096-5114	2.3	1
14	dfcomb: An R-package for phase I/II trials of drug combinations. <i>Computer Methods and Programs in Biomedicine</i> , 2016 , 125, 117-33	6.9	1

13	Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior elicitation. <i>Pharmaceutical Statistics</i> , 2019 , 18, 198-211	1	1
12	Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. <i>Archives of Disease in Childhood</i> , 2018 , 103, 1067-1075	2.2	1
11	The Continual Reassessment Method 2006 , 131-148		0
10	Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'. <i>Statistics in Medicine</i> , 2016 , 35, 475-8	2.3	
9	An adaptive model switching approach for phase I dose-finding trials. <i>Pharmaceutical Statistics</i> , 2013 , 12, 225-32	1	
8	Phase I/II Clinical Trials 2014 , 658-666		
7	Dose Estimation. <i>Pharmaceutical Medicine</i> , 2008 , 22, 35-40	2.3	
6	Identifying the Most Successful Dose (MSD) in Dose-Finding Studies 2008 , 1		
5	Phase I/II Clinical Trials 2007 , 1		
4	Defining Stopping Rules 2006 , 205-224		
3	Websites and Software 2006 , 287-306		
2	Identifying the Most Successful Dose (MSD) in Dose-Finding Studies 2005 , 1-5		
1	Competing Risks Model with Short-Term and Long-Term Covariate Effects for Cancer Studies. <i>Statistics in Biosciences</i> , 2021 , 13, 142-159	1.5	